- Home
- AGMB vs SCZM Comparison
AGMB vs SCZM Comparison
Compare AGMB & SCZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGMB | SCZM |
|---|---|---|
| Founded | 2017 | N/A |
| Country | Belgium | Canada |
| Employees | N/A | 455 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.5M | 585.2M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGMB | SCZM |
|---|---|---|
| Price | $13.90 | $9.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $32.00 | $12.00 |
| AVG Volume (30 Days) | 151.8K | ★ 462.3K |
| Earning Date | 04-23-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $79.38 |
| Revenue Next Year | $17.86 | N/A |
| P/E Ratio | ★ N/A | $14.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.75 | $5.61 |
| 52 Week High | $17.82 | $17.65 |
Technical Indicators
Market Signals| Indicator | AGMB | SCZM |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 55.66 |
| Support Level | $13.90 | $8.67 |
| Resistance Level | $14.94 | $10.15 |
| Average True Range (ATR) | 1.22 | 0.54 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 34.28 | 46.82 |
Price Performance
Historical ComparisonAbout AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
About SCZM Santacruz Silver Mining Ltd. Common Shares
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapa mine and processing plant, and Corporate and Other activities. Key revenue is generated from Zimapan.